{"drugs":["Albumin, Iodinated I-125"],"mono":{"0":{"id":"926732-s-0","title":"Generic Names","mono":"Albumin, Iodinated I-125"},"1":{"id":"926732-s-1","title":"Dosing and Indications","sub":{"0":{"id":"926732-s-1-4","title":"Adult Dosing","mono":"<ul><li>premedicate with Lugol's solution (Strong Iodine Solution USP) 10 drops ORALLY three times daily starting at least 24 hours before administration of iodinated albumin I-125; continue 1 to 2 weeks after procedure<\/li><li><b>Blood volume estimation; Diagnosis:<\/b> 0.185 to 1.85 megabecquerels (5 to 50 microcuries) IV; MAX 7.4 megabecquerels (200 microcuries) weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks after procedure<\/li><li><b>Plasma volume measurement; Diagnosis:<\/b> 0.185 to 1.85 megabecquerels (5 to 50 microcuries) IV; MAX 7.4 megabecquerels (200 microcuries) weekly for repeated dosing; premedicate with Lugol's solution 10 drops ORALLY three times daily starting at least 24 hours before administration, continue 1 to 2 weeks after procedure<\/li><\/ul>"},"3":{"id":"926732-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Blood volume estimation; Diagnosis<\/li><li>Plasma volume measurement; Diagnosis<\/li><\/ul>"}}},"3":{"id":"926732-s-3","title":"Contraindications\/Warnings","sub":[{"id":"926732-s-3-9","title":"Contraindications","mono":"specific contraindications have not been determined <br\/>"},{"id":"926732-s-3-10","title":"Precautions","mono":"<ul><li>cisternography use; reported cases of hyperpyrexia and aseptic chemical meningeal irritation<\/li><li>standard radioactivity precautions<\/li><li>women of childbearing capability<\/li><\/ul>"},{"id":"926732-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"926732-s-3-12","title":"Breast Feeding","mono":"<ul><li>AAP: Radioactive compounds that require temporary cessation of breastfeeding.<\/li><li>Micromedex: Infant risk cannot be ruled out.<\/li><\/ul>"}]},"5":{"id":"926732-s-5","title":"Adverse Effects","mono":"<b>Serious<\/b><ul><li><b>Neurologic:<\/b>Meningeal irritation<\/li><li><b>Other:<\/b>Hyperpyrexia<\/li><\/ul>"},"6":{"id":"926732-s-6","title":"Drug Name Info","sub":{"2":{"id":"926732-s-6-19","title":"Class","mono":"Diagnostic Agent<br\/>"},"3":{"id":"926732-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"926732-s-7","title":"Mechanism Of Action","mono":"Iodinated I-125 albumin is a diagnostic radiopharmaceutical that acts by uniformly distributing into the intra- and extravascular spaces, thereby allowing for use in determination of total blood and plasma volumes.<br\/>"},"8":{"id":"926732-s-8","title":"Pharmacokinetics","sub":{"3":{"id":"926732-s-8-26","title":"Excretion","mono":"<ul><li>Renal: significant urinary excretion<\/li><li>Feces: approximately 2%<\/li><\/ul>"},"4":{"id":"926732-s-8-27","title":"Elimination Half Life","mono":"normal subjects, approximately 14 days <br\/>"}}},"9":{"id":"926732-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>use proper procedures for handling and disposal of radiopharmaceuticals<br\/><\/li><li><b>Intravenous<\/b><br\/><ul><li>remove an aliquot from vial identical in volume to dose to be administered to patient<\/li><li>prepare reference solution using normal saline as a diluent; recommended dilution 1:4000<\/li><li>determine radioactivity of reference solution<\/li><li>inject dose into large vein in arm, measure residual radioactivity in both syringe and needle<\/li><li>withdraw blood sample at 5 and 15 minutes from other arm after injecting dose; use sterile heparinized syringe<\/li><li>take a known aliquot from each blood sample and determine radioconcentration; for plasma volume concentration, blood is centrifuged and red blood cells are removed<\/li><li>determine background blood radioconcentration if repeated blood volume or blood plasma measurements are necessary<\/li><\/ul><\/li><\/ul>"},"10":{"id":"926732-s-10","title":"Monitoring","mono":"no specific monitoring has been determined<br\/>"},"13":{"id":"926732-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug is excreted in breast milk. Use formula-feedings in place of breastfeedings.<\/li><li>Advise women of childbearing potential that examinations, especially those elective in nature, are ideally performed during the first few days (approximately 10 days) following onset of menses.<\/li><\/ul>"}}}